HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

CD30-targeted therapy with brentuximab vedotin and DLI in a patient with T-cell posttransplantation lymphoma: induction of clinical remission and cellular immunity.

AuthorsSebastian Theurich, Kerstin Wennhold, Inga Wedemeyer, Achim Rothe, Kai Hübel, Alexander Shimabukuro-Vornhagen, Udo Holtick, Michael Hallek, Christof Scheid, Michael von Bergwelt-Baildon
JournalTransplantation (Transplantation) Vol. 96 Issue 3 Pg. e16-8 (Aug 15 2013) ISSN: 1534-6080 [Electronic] United States
PMID23917689 (Publication Type: Case Reports, Letter)
Chemical References
  • Immunoconjugates
  • Ki-1 Antigen
  • Brentuximab Vedotin
Topics
  • Aged
  • Brentuximab Vedotin
  • Female
  • Hematopoietic Stem Cell Transplantation (adverse effects)
  • Humans
  • Immunity, Cellular
  • Immunoconjugates (therapeutic use)
  • Ki-1 Antigen (antagonists & inhibitors)
  • Lymphocyte Transfusion
  • Lymphoma, T-Cell (drug therapy, etiology, immunology)
  • Remission Induction
  • Transplantation, Homologous

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: